Alan Crane

Jun 23, 2015

Alan Crane has resigned from the board of T2 Biosystems, effective immediately, in order to pursue other business opportunities, the company said in a document filed with the US Securities and Exchange Commission. Crane served on the firm's compensation committee. 

More Like This

Jun 18, 2018

Joseph Caruso

LexaGene announced today that it has appointed Joseph Caruso to the firm's board of directors. Caruso currently serves as a member of the board of directors and operating committee at Endocellutions. Caruso was previously CEO and chairman of Palomar Medical Technology until the firm's sale in 2013. 

Jun 15, 2018

Lihau Yu

Eisai announced today that it has appointed Lihau as president and chief data sciences officer of H3 Biomedicine, the cancer genomics-based drug discovery company of Eisai. Yu will be responsible for the overall scientific and business direction of H3, where she joined H3 in 2011. Yu previously spent 12 years at AstraZeneca. 

Jun 13, 2018

Lawrence Firestone

Akonni Biosystems has appointed Lawrence Firestone to the role of executive vice president and CFO to bring the company through the commercialization phase of its business plan. Firestone has previously served as CEO, CFO, and COO in various technology firms.

Jun 13, 2018

Rohan Hastie, John Ryals,

Rohan Hastie was named president and CEO of Metabolon. He replaces John Ryals, who retired from those posts, but will remain on the company's board. Ryals has been president, CEO, and a board member of Metabolon since April 2002, when he cofounded the firm. 

Hastie joined Metabolon in September 2017 as chief business officer. Before that, he was president of consulting firm Arrow Life Sciences & Healthcare. He also has held leadership positions in diagnostics and corporate development at Hologic, where he was most recently president of Hologic Diagnostic Solutions.

Jun 12, 2018

Michael McCartney

Cancer Genetics has appointed Michael McCartney its chief commercial officer, effective immediately. McCartney was previously CEO of SciKon Innovation, an early-stage life science company. Before that, he was SciKon's COO. He has more than 20 years of experience in the life science space including stints at Roche, Siemens, and Abbott. 

Jun 08, 2018

Gerald Herman

Bruker announced that it has hired Gerald Herman as its new CFO. He replaces Anthony Mattacchione, whose resignation was announced in February. Herman joined Bruker in 2016 as VP and corporate controller, and has been serving as interim CFO since March 2018. He previously served a corporate VP - Clinical Operations of Parexel International from 2014 to February 2016, and as corporate VP and controller-finance of Parexel from 2008 to 2013. Prior to 2008, he was VP - corporate controller of Presstek.

Jun 06, 2018

Michael Hultner

PetaGene has appointed Michael Hultner as senior vice president and general manager of US operations. Hultner will be responsible for growng the company's commercial operations and client support in the US while contributing to the strategic direction of PetaGene and its products, which include PetaSuite and PetaSuite Cloud Edition for genomic data compression. Hultner joins PetaGene from Seven Bridges, where he was chief strategy officer and general manager of national programs. Prior to that he was chief scientist at Leidos, and he has held several executive positions at Lockheed Martin Health & Life Sciences.

Jun 06, 2018

Bob Englert, Steve Crouse

Vortex Biosciences has appointed Bob Englert as its new CEO. Englert, who was previously the firm's chief technology officer, replaces exiting CEO Gene Walther, who has resigned to pursue other interests and will step down both from his position as CEO and as a member of the company's board.

Englert has over 25 years of experience in medical devices and life sciences, with a particular focus on IVD, point of care, and digital health solutions. Before joining Vortex, he served as CEO and founder of Biomedtrics, a diabetes data management company, and prior to that he was COO of Pelikan Technologies. Earlier in his career, Englert also held multiple senior roles at Abbott Laboratories. He holds a BS in biology from the University of Illinois Urbana-Champaign.

Vortex also said that Steve Crouse, who has been the company's chief commercial officer since March 2016, will now assume the position of chief operating officer. Prior to joining Vortex, Crouse served as senior vice president of sales and marketing at Freeslate, a company focused on providing laboratory automation to chemical and pharmaceutical companies.

Jun 01, 2018

Ben Ho Park

Vanderbilt has announced that Ben Ho Park has been named co-leader of the breast cancer research program, director of the precision oncology, and associate director for translational research at the Vanderbilt-Ingram Cancer Center. Park, who will assume the post Sept. 1, succeeds Carlos Arteaga. Park currently serves as professor of oncology in the bresat and ovarian cancer program, associate director for research training and education, and member of the executive oversight committee at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. Park received his undergraduate degree from the University of Chicago, followed by dual training at the University of Pennsylvania School of Medicine. 

May 31, 2018

Ted Goldstein

Precision medicine informatics company GNS Healthcare has named bioinformatician and biomedical engineer Ted Goldstein to its strategic advisory board. Goldstein, scientific program director of computational health at the University of California, San Francisco, is leading development of a machine learning-based comprehensive cancer diagnosis and treatment model for the university. He previously was vice president of developer tools at Apple and an e-commerce hardware developer for Sun Microsystems. 

May 29, 2018

Craig Venter

Craig Venter said last week that he is retiring from Human Longevity, a company he co-founded and where he serves as chairman and CEO. Venter said in a Tweet that he will be returning to the J. Craig Venter Institute, which he founded in 2006, "to continue my work."

May 25, 2018

Cynthia Collins

DermTech, a developer of non-invasive molecular dermatology tests, has appointed Cynthia Collins to its board of directors. Collins most recently served as CEO of Human Longevity. She has also been CEO/GM of GE Healthcare's cell therapy business, lab businesses, and Clarient Diagnostics. Prior to GE, Collins was president and CEO of GenVec. Before that she was group vice president for the cellular analysis business at Beckman Coulter. She has also held executive positions with Sequoia Pharmaceuticals and Clinical Micro Sensors, a subsidiary of Motorola.

May 24, 2018

Craig Mak

Arbor Biotechnologies has appointed Craig Mak as director of strategy. Prior to joining Arbor, Mak served as the editor of Cell Systems, as a senior editor at Nature Biotechnology, and as a software engineer at Sun Microsystems. 

May 24, 2018

Michael Sanderson

Michael Sanderson has been appointed CEO of PierianDx and director of the company's board. Sanderson has more than 25 years in the healthcare industry, mostly in healthcare analytics and big data. Most recently he has been a consultant focused on health IT and analytics, according to his LinkedIn profile. He was previously president and cofounder of RemitData.

May 23, 2018

Mike Nolan

Freenome has hired Mike Nolan as its chief commercial officer. In his new position, Nolan will be responsible for bringing Freenome's first AI-generated, genomic cancer screening test, a blood test for colorectal cancer, to market. Most recently, Nolan was senior vice president of commercial operations at Foundation Medicine. Overall, he has more than 25 years of experience in strategic management and commercial leadership at companies such as Thermo Fisher Scientific, Life Technologies, Luminex, and Roche Diagnostics.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.